CYNAPSUS THERAPEUTICS

cynapsus-therapeutics-logo

Cynapsus is a pharmaceutical company that focuses on developing a non-injectable drug for Parkinson’s disease. The company specializes in the fields of healthcare, biotechnology, pharmaceutical, and therapeutics. It was founded in 2004 and headquartered in Toronto, Ontario.

#SimilarOrganizations #People #Financial #Website #More

CYNAPSUS THERAPEUTICS

Social Links:

Industry:
Biotechnology Health Care Pharmaceutical

Founded:
2004-01-01

Address:
Toronto, Ontario, Canada

Country:
Canada

Website Url:
http://www.cynapsus.ca

Total Employee:
11+

Status:
Closed

Contact:
416-703-2449

Email Addresses:
[email protected]

Total Funding:
36.68 M USD

Technology used in webpage:
Apple Whitelist


Similar Organizations

apellis-pharmaceuticals-logo

Apellis Pharmaceuticals

Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.

aveo-oncology-logo

AVEO Oncology

AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.

iveric-bio-logo

IVERIC bio

IVERIC bio is a biopharmaceutical company developing novel therapies for age-related macular degeneration.

recro-pharma-logo

Recro Pharma

Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.

Current Employees Featured

anthony-giovinazzo_image

Anthony Giovinazzo
Anthony Giovinazzo President and CEO @ Cynapsus Therapeutics
President and CEO

Founder


not_available_image

Andrew Williams

Stock Details


Company's stock symbol is CVE:CTH

Investors List

aisling-capital_image

Aisling Capital

Aisling Capital investment in Venture Round - Cynapsus Therapeutics

venrock_image

Venrock

Venrock investment in Venture Round - Cynapsus Therapeutics

orbimed-advisors_image

OrbiMed

OrbiMed investment in Venture Round - Cynapsus Therapeutics

Official Site Inspections

http://www.cynapsus.ca

  • Host name: 104.21.112.1
  • IP address: 104.21.112.1
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Cynapsus Therapeutics"

About :: Cynapsus Therapeutics Inc. (CYNA)

Cynapsus has initiated its pivotal Phase 3 clinical program for APL-130277, and will rely on the abbreviated Section 505(b)(2) regulatory pathway in the United States. The Company intends …See details»

Company Information :: Cynapsus Therapeutics Inc. (CYNA)

Cynapsus is a specialty central nervous system pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand …See details»

Cynapsus Therapeutics - Wikipedia

Cynapsus Therapeutics Inc. is a specialty pharmaceutical company developing a drug to treat the motor symptoms of Parkinson's disease. Based in Toronto, Ontario, Canada. Formerly named Cannasat Therapeutics they changed their name to Cynapsus Therapeutics in 2010. In September 2016, Sunovion (a subsidiary of Dainippon Sumitomo Pharma) a…See details»

Cynapsus Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...

Explore Cynapsus Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 7 news, and 2 literature, Drug:CAT-210.See details»

Cynapsus Therapeutics - Crunchbase Company Profile …

Contact Email [email protected]; Phone Number 416-703-2449; Cynapsus is a pharmaceutical company that focuses on developing a non-injectable drug for Parkinson’s disease. The company specializes in the fields of healthcare, …See details»

Cynapsus Therapeutics Inc | Cambridge House International

Cynapsus is a specialty pharmaceutical company developing the only non-injectable (i.e. sublingual) delivery of the only approved drug (apomorphine) to be used as a rescue therapy …See details»

Cynapsus Company Profile 2024: Valuation, Investors, Acquisition ...

Cynapsus General Information Description. Operator of a specialty central nervous system (CNS) pharmaceutical company. The company develops a sublingual thin film for the potential …See details»

Corporate Governance :: Cynapsus Therapeutics Inc. (CYNA)

Board Members Committees; Rochelle Stenzler. Chair of the Board of Directors. Audit CommitteeSee details»

Cynapsus Therapeutics Inc Com N - The Globe and Mail

Nov 16, 2005 Real-time Price Updates for Cynapsus Therapeutics Inc Com N (CYNAD), along with buy or sell indicators, analysis, charts, historical performance, news and moreSee details»

Cynapsus Therapeutics Inc. - Toronto, Canada - bionity.com

Cynapsus is a specialty clinical development pharmaceutical company targeting diseases of the brain. Cynapsus has a lower risk Parkinson's drug candidate ("APL-130277"), which is a …See details»

Cynapsus Therapeutics | VentureRadar

Morpheus Biolabs USA n/a Morpheus BioLabs is a Contract Research Organization (CRO) that is specialized in providing biomedical research and consulting services to pharmaceuticals, …See details»

Cynapsus Therapeutics raises $21 mln in deal led by U.S. VCs

Apr 7, 2015 Cynapsus Therapeutics Anthony Giovinazzo President and CEO (416) 703-2449 x225 [email protected] Andrew Williams COO & CFO (416) 703-2449 x253 …See details»

Cynapsus Therapeutics

Williams joined Cynapsus from Global Mentoring Solutions (GMS), where he was Vice President of Strategic Planning. GMS is a leading provider of learning support programs and services for …See details»

Sunovion Pharma to buy Canada's Cynapsus for $624 million

Aug 31, 2016 Sunovion Pharmaceuticals Inc, a unit of Japan's Dainippon Sumitomo Pharma Co Ltd <4506.T>, said it would buy Canada's Cynapsus Therapeutics Inc <CTH.TO> <CYNA.O> …See details»

Sunovion pays $624M for Canada’s Cynapsus, lead PhIII …

Sep 1, 2016 Sunovion Pharmaceuticals is to pay a 120% premium to buy out Canadian biotech Cynapsus Therapeutics as it looks to get its hands on the company’s late-stage Parkinson’s …See details»

CYNA (CYNA) Stock Price, News & Analysis - MarketBeat

Dec 28, 2024 Cynapsus Therapeutics Inc is a Canada-based specialty central nervous system (CNS) pharmaceutical company. It develops a sublingual thin film for the potential treatment …See details»

Cynapsus Therapeutics

Jun 30, 2007 June 25, 2022 Cynapsus Therapeutics’ APL-130277 Improved Parkinson’s Symptoms and Rapidly Turned Patients from OFF to ON in Data Presented at the …See details»

Cynapsus Therapeutics

Dr. Thierry Bilbault is Cynapsus' Chief Scientific Officer and Executive Vice President, CMC. He is a global pharmaceutical development and manufacturing operations leader with over 20 years …See details»

Cynapsus Therapeutics, Inc. (Cynapsus Therapeutics, Inc.) - 药物管 …

He was the Chief Executive Officer and Director of Cynapsus Therapeutics, a NASDAQ listed specialty pharmaceutical company that developed the first successful sublingual apomorphine …See details»

linkstock.net © 2022. All rights reserved